Biological kits for the laboratory of pathology. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis and identify potential targets for rational personalized…
Ended Purchase Order Awarded Last action
- Contract number
- 75N91025P00388
- Awardee
-
Invivoscribe, Inc. UEI R1EVMK8MEZS9
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $18,196
Award facts
- Contract value 100% obligated
- $18,195.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92121, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$224 | |
| Original award | $18,420 |
About this award
This federal contract award is for the procurement of biological kits for the Laboratory of Pathology at the National Cancer Institute (NCI), a component of the U.S. Department of Health and Human Services. The contract, valued at $18,195.96, was awarded to Invivoscribe, Inc., a for-profit manufacturer of goods specializing in precision diagnostics, molecular testing, and biological research products. The contract is a firm fixed-price purchase order with an ultimate completion date of June 27, 2025. The requested products are intended to support the laboratory's work in developing tests that assist in pathologic diagnosis, prognosis prediction, and identification of potential targets for personalized cancer therapies. This award was competitively obtained without any set-aside designation, indicating Invivoscribe's selection was based on its specialized expertise in the required biological products.
Description
Biological kits for the laboratory of pathology. The laboratory develops tests that assist in pathologic diagnosis, predict prognosis and identify potential targets for rational personalized therapies. IT is currently the only clia and college of a
Quick answers
Who was awarded contract 75N91025P00388?
75N91025P00388 was awarded to Invivoscribe, Inc. by National Cancer Institute (National Institutes of Health) on May 8, 2025.
How much is contract 75N91025P00388 worth?
The government has obligated $18,196 on 75N91025P00388.
Was contract 75N91025P00388 competed?
The extent of competition for 75N91025P00388 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award